Abstract
A nursery rhyme, which some of us learned when we were children brought tinker, tailor, soldier, and sailor together (Opie and Opie, 1951), rather like this volume, where its authors have been convened from many disciplines to describe how the diverse indexes of our individuality—our proteins—can be handled for biomedical purposes. My contribution to the mix is a chapter on strategies about enzyme replacement therapy; other authors provide the tactical details upon which the successful campaign for such treatment will depend.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Austin, J. H., 1967, Some recent findings in leukodystrophies and in gargoylism, in: Inborn Disorders of Sphingolipid Metabolism, (S. M. Aronson and B. W. Volk, eds.) p. 359, Pergamon Press, Inc., Oxford.
Baudhuin, P., Hers, H. G., and Leob, H., 1964, An electron microscopic and biochemical study of type II glycogenosis, Lab. Invest. 13:1139.
Bickel, H., Schultze, H. E., Bruter, W., and Gollner, I., 1956, Versuche zur Coeruloplasminsubstitution bei der hepatocerebralen Degeneration (Wilsonsche Krankheit), Kiln. Wochschr. 34:961.
Boyer, S. M., Siggers, D. C., and Krugger, L. J., 1973, Caveat to protein replacement therapy for genetic disease: immunological implications of accurate molecular diagnosis, Lancet 2:654
Brady, R. O., Tallman, J. F., Johnson, W. G., Gal, A. E., Leahy, W. R., Quirk, J. M., and Dekaban, A. S., 1973, Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosi-dase in Fabry’s disease, New Engl. J. Med. 289:9.
Brady, R. O., Penchev, P. G., Gal, A. E., Hebert, S. R., and Dekaban, A. S., 1974, Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher’s disease, New Engl. J. Med. 291:989.
Bunting, P. S., and Laidler, K. J., 1972, Kinetic studies on solid-supported ß-galactosidase. Biochemistry 11:4477.
Canadian Council on Animal Care, Animal Resources Committee, 1976, Index of Vertabrate Stocks for Research in Canada.
Carter, C. O., 1956, Changing patterns in the causes of death at the Hospital for Sick Children, Great Ormond Street Journal 11:65.
Cass, J., 1973, One medicine—human and veterinary, Perspectives Biol. Med. 16:418. Cederholm-Williams, S. A., 1973, Insoluble enzymes—therapeutic potential, in: Treatment of Inborn Errors of Metabolism (J. W. T. Seakins, R. A. Saunders, and C. Toothill, eds.), SSIEM Symposium No. 10, p. 195, Churchill, Livingston, London.
Chang, T. M. S., 1964, Semipermeable microcapsules, Science 146:524.
Chang, T. M. S., 1972, Artificial Cells, Charles C. Thomas Pub., Springfield, Ill.
Chang, T. M. S., and Poznansky, M. J., 1968, Semipermeable microcapsules containing calatase for enzyme replacement in acalatosalmic mice. Nature 218:243.
Chang, T. M. S., Gonda, A., Dirks, J. H., Coffey, J. F., and Lee-Burns, T., 1972, ACAC microcapsule artificial kidney for the long term and short term management of eleven patients with chronic renal failure, Trans. Amer. Soc. Artificial Internal Organs 18:465.
Childs, B., and Der Kaloustian, M., 1968, Genetic heterogeneity, New Engl. J. Med. 279:1205, 1267
Childs, B., Miller, S. M., and Beam, A. G., 1972, Gene mutation as a cause of human disease, in: Mutagenic Effects of Environmental Contamination, (H. E. Sutton, and M. I. Harris, eds.), p. 3, Academic Press, Inc. New York.
Clarke, J. T. R., Guttman, R. D., Wolfe, L. S., Beaudoin, J. G., and Morehouse, D. D., 1972, Enzyme replacement therapy by renal allotransplantation in Fabry’s disease, New Engl. J. Med. 287:1215
Cornelius, C. E., 1969, Animal models—a neglected medical resource, N. Engl. J. Med. 281:934
Cuatrecasas, P., Wilchek, M., and Anfinsen, C. B., 1968, Selective enzyme purification by affinity chromatography, Proc. Natl. Acad. Sci. U. S. 61:636.
Daloze, P., Delvin, E. D., Glorieux, F. H., Gorman, J., and Bettez, P., 1974, Replacement therapy for inherited enzyme deficiency: liver orthotopic transplantation in Niemann-Pick disease type A, Clin. Res. 23:739A.
Day, N., and Holmes, L. B., 1973, The incidence of genetic disease in a university hospital population, Amer. J. Human Genet. 25:237.
Dean, M. F., Muir, H., and Benson, P. F., 1973, Mobilization of glycosaminoglycans by plasma infusion in mucopolysaccharidosis type III—two types of response, Nature New Biol. 243:143.
deBarsy, T., Jacquemin, P., van Hoof, F., and Hers, H. G., 1973, Enzyme replacement in Pompe disease: an attempt with purified human acid a-glucosidase, in: Enzyme Therapy in Genetic Diseases, Birth Defects (Original Article Series, Vol. 9) (R. J. Desnick, R. W. Bernlohr, and W. Krivit, eds.), p. 184, The Williams & Wilkins Company, Baltimore.
DeKaban, A. S., Holden, K. R., and Constantopoulos, G., 1972, Effects of fresh plasma or whole blood transfusions on patients with various types of mucopolysaccharidosis, Pediatrics 50:688.
Desnick, R. J., Allen, K. Y., Simmons, R. L., Majarian, J. S., and Krivit, W., 1971, Treatment of Fabry’s disease: correction of the enzymatic deficiency by renal transplantation, J. Lab. Clin. Med. 78:989.
Desnick, R. J., Krivit, W., Synder, P. D., Desnick, S. J., and Sharp, H. L., 1972, Sandhoffs disease: ultrastructural and biochemical studies, in: Sphingolipidoses and Allied Disorders (S. M. Aronson and B. W. Volk, eds.), p. 351, Plenum Press, New York.
Desnick, R.J., Simmons, R. L., Allen, K. Y., Woods, J. E., Anderson, C. F., Najarian, J. S., and Krmit, W., 1972, Correction of enzymatic deficiencies by renal transplantation: Fabry’s Disease, Surgery 72: 203.
Desnick, R. J., Krivit, W., and Fiddler, M. B., 1975a, Enzyme Therapy in Genetic Diseases: Progress, Principles and Prospects, in: The Prevention of Genetic Disease and Mental Retardation (A. Milunsky, ed.), p. 317, W. B. Saunders. Philadelphia.
Desnick, R. J., Thorpe, S. R., Steger, L., Dullum, D., Cumming, D., and Fiddler, M., 1975b, Enzyme replacement therapy: in vivo fate of nature, erythrocyte and liposome entrapped ß-glucuronidase, Pediat. Res. 9:312.
DiFerrante, N., Nichols, B. L., Donnelly, P. V., Neri, G., Hrgovcic, R., and Berglund, R. K., 1971, Induced degradation of glycosaminoglycans in Hurler’s and Hunter’s syndromes by plasma infusion, Prot Natl. Acad. Sci. U.S. 68:303.
Dumond, D. E., 1975, The limitation of human population: a natural history, Science 187:713
Earley, K., 1975, Disinheriting disease in “The Sciences” N. Y. Acad. Sci. 15(5):19.
Erickson, R. P., Sandman, R., van B. Robertson, W., and Epstein, C. J., 1972, Inefficacy of fresh frozen plasma therapy of mucopolysaccharidosis II, Pediatrics 50:693.
Farrell, D. F., Baker, H. J., Herndon, R. M., Lindsey, J. R., and McKhann, G. M., 1973, Feline GM, gangliosidosis: biochemical and ultrastructural comparisons with the disease in man, J. Neuropathol. Exptl. Neurol. 32:1.
Feinstein, R. N., Howard, J. B., Braun, J. T., and Seaholm, J. E., 1966, Acatalasemic and hyposemic mouse mutants, Genetics 53: 923.
Fernandes, J., and Hulling, F., 1968, Branching-enzyme-deficiency glycogenosis: studies in therapy, Arch. Disease Childhood 43:347.
Friedman, M., and Byers, S. O., 1948, Observations concerning the causes of the excess excretion of uric acid in the Dalmatian dog, J. Biol. Chem. 175:727.
Garrod, A. E., 1902, The incidence of alcaptonuria: a study in chemical individuality, Lancet 2: 1616.
Giblett, E. R., Anderson, J. E., Cohen, F., Pollara, F., and Meuwissen, H. J., 1972, Adenosine-deaminase deficiency in two patients with severly impaired cellular immunity, Lancet 2:1067.
Gillette, P. N., Peterson, C. M., Lin, Y. S., and Cerami, A., 1974, Sodium cyanate as a potential treatment for sickle cell disease, New Engl. J. Med. 290:654.
Goldman, H., Scriver, C. R., Aaron, K., and Pinsky, L., 1970, Use of dithiothreitol to correct cystine storage in cultured cystinotic fibroblasts, Lancet 1:811.
Goldman, H., DePape-Brigger, D., Delvin, E., and Scriver, C. R., 1974, Long-term use of oral dithiothreitol (DTT) in nephropathic cystinosis, Clin. Res. 22:740A.
Goldstein, L., and Katchalski, E., 1968, Use of water-insoluble enzyme derivatives in biochemical analysis and separation, Z. Fur analyt. Chemie 243:375.
Greene, H. L., Hug, G., and Schubert, W. K., 1969, Metachromatic leucodystrophy: treatment with arylsulfatase-A, Arch. Neurol. 20:147.
Gregoriadis, G., 1973, Molecular Trojan Horses, New Scientist, Dec., p. 890.
Gregoriadis, G., 1974, Structural requirements for the specific uptake of macromolecules and liposomes by target tissues, in: Enzyme therapy in lysosomal storage disease. (J. M. Tager, G. J. M. Hooghwichel, and W. T. H. Daems, eds.), p. 131, North Holland Pub. Co., Amsterdam.
Gregoriadis, G., and Ryman, B. E., 1972a, Fate of protein-containing liposomes injected into rats. An approach to the treatment of storage diseases, Eur. J. Biochem. 24:485.
Gregoriadis, G., and Ryman, B. E., 1972b, Lysosomal localization of ß-fructofuranosidase containing lipcsomes injected into rats. Some implications in the treatment of genetic disorders, Biochem. J. 129:123.
Gregoriadis, G., Leatherwood, P. D., and Ryman, B. E., 1971, Enzyme entrapment in liposomes, FEBS Letters 14:95.
Harris, H., 1968, Molecular basis of hereditary disease, Brit. Med. J. 1:135.
Harris, H., and Hopkinson, D. A., 1972, Average heterozygosity per locus in man: an estimate based on the incidence of enzyme polymorphism, Ann. Human Genet. 36:9.
Hirschhorn, R., 1975, Conversion of human erythrocyte-adenosine deaminase activity to different tissue-specific isozymes: evidence for a common catalytic unit, J. Clin. Invest. 55:661
Hors-Cayla, M. C., Maroteaux, P., and deGrouchy, J., 1968, Fibroblastes en culture au cours de mucopolysaccharidoses: influence du serum sur la métachromasie, Ann. Genetique 11:265
Hsia, Y. E., 1975, Treatment in genetic diseases, in: The Prevention of Genetic Disease and Mental Retardation (A. Milunsky, ed.) p. 277, W. B. Saunders Company, Philadelphia.
Hug, G., and Schubert, W. K., 1967a, Hepatic lysosomes in Pompe’s disease: disappearance during glucosodase administration, J. Clin. Invest. 46:1073.
Hug, G., and Schubert, W. K., 1967h, Lysosomes in type II glycogenosis: changes during administration of extract from Aspergillus niger, J. Cell Biol. 35:C1.
Hug, G., Schubert, W. K., and Chuck, G., 1968, Type II glycogenosis: treatment with extract of Aspergillus niger, Clin. Res. 16:345.
Huijing, F., Waltuck, B. L., and Whelan, W. J., 1973, Alpha-glucosidase administration: experiences in two patients with glycogen storage disease compared with animal experiments, in: Enzyme Therapy in Genetic Diseases, Birth Defects (Original Article Series, Vol. 9) (R. J. Desnick, R. W. Bernlohr, and W. Krivit, eds.), p. 191, The Williams & Wilkins Company, Baltimore.
Ihler, G. M., Glew, R. M., and Schrure, F. W., 1973, Enzyme loading of ervthrocctes, Proc. Nat. Acad. Sci. Wash. 70:2663.
Jensen, M., Bunn, H. F., Halikas, G., Kan, Y. W., and Nathan, D. G., 1973, Effects of cyanate and 2,3diphosphoglycerate on sickling: relationship to oxygeneration, J. Clin. Invest. 52:2542.
Johnson, W. G., Desnick, R. J., Long, D. M., Sharp, H. L., Krivit, W., Brady, B., and Brady, R. O., 1973, Intravenous injection of purified hexosaminidase A into a patient with Tay—Sachs disease, in: Enzyme Therapy in Genetic Diseases, Birth Defects: (Original Article Series, Vol. IX) (R. J. Desnick, R. W. Bernlohr, and W. Krivit, eds.), p. 120, The Williams and Wilkins Co., Baltimore.
Jones, T. C., Rachel, D. B., and Migaki, K., 1973, (eds.), The Registry of Comparative Pathology; Animal Models of Human Disease, Baltimore Information Services, Inc., Baltimore.
Kanfer, J. N., Legler, G., Sullivan, J., Raghavan, S. S., and Mumford, R. A., 1975, The Gaucher mouse, Biochem. Biophys. Res. Commun. 67:85.
Katz, J. J., and Crespi, H. L., 1971, Isotope effects in biological systems, in: Isotope Effects in Chemical Reactions. (C. J. Collins and N. S. Bowman, edti.), p. 286, Van Nostrand Reinhold, New York.
Keightley, R. G., Lawton, A. R., Cooper, M. D., and Yunis, E. J., 1975, Successful fetal liver transplantation in a child with severe combined immunodeficiency, Lancet 2:850.
Knudson, A. G., Jr., DiFerrante, N., and Curtis, J. E., 1971, Effect of leucocyte transfusion in a child with type II mucopolysaccharidosis, Proc. Natl. Acad. Sci. U. S. 68:1738.
Kolodny, E. H., 1973, commentary in: Enzyme Therapy in Genetic Diseases,Birth Defects (Original Article Series, Vol. 9) (R. J. Desnick, R. W. Bernlohr, and W. Krivit, eds.), p. 40, The Williams & Wilkins Company, Baltimore.
Lauer, R. M., Mascarinas, T., Racela, A. S., Diehl, A. M., and Brown, B. I., 1968, Administration of a mixture of fungal glucosidases to a patient with type II glycogenesis (Pompe’s disease), Pediatrics 42:672.
Levy, N. L., Synderman, R., Ladda, R. L., and Lieberman, R., 1973, Cytogenetic engineering in vivo: restoration of biologic complement activity to C5-deficient mice by intravenous inoculation of hybrid cells, Proc. Natl. Acad. Sci. U. S. 70:3125.
Lubin, B. H., Pena, V., Mentzer, W. C., Bymun, E., Bradley, T. B., and Pacher, L., 1975, Dimethyl adipimidate: a new antisickling agent, Proc. Natl. Acad. Sci. U. S. 72:43.
Lush, I. E., 1967, The biochemical genetics of vertebrates except man, in: Frontiers of Biology, Vol. 3, (A. Neuberger, and E. L. Tatum, eds.), p. 118, North-Holland Publishing Co., Amsterdam
Mapes, C. A., Anderson, R. L., Sweeley, C. C., Desnick, R.J., and Krivit, W., 1970, Enzyme replacement in Fabry’s disease: an inborn error of metabolism, Science 169:987.
McKusick, V. A., 1975, Mendelian inheritance in man, in: Catalogs of Autosomal Dominant, Autosomal Recessive and X-Linked Phenotypes, 4th ed., The Johns Hopkins Press, Baltimore.
Merrifield, R. B., 1967, New approaches to the chemical synthesis of peptides, Recent Progr. Hormone Res. 23:451.
Mosback, K., 1970, Matrix-bound enzymes, Part I: The use of different acrylic copolymers as matrices, Acta Chem. Scand. 24:2084.
Motulsky, A. G., and Boman, H., 1974, Genetics and artherosclerosis, in: Proc. 3rd Int. Symp. Artherosclerosis, Oct. 1973 (G. Schettler, and A. Weizel, eds.), Springer-Verlag, Berlin.
Neckers, D. C., 1975, Solid phase synthesis, J. Chem. Educ. 52:695.
Neufeld, E. F., and Cantz, M. J., 1971, Corrective factors for inborn errors of mucopolysaccharide metabolism, Ann. N. Y. Acad. Sci. 179:580.
Norden, A. G. W., and O’Brien, J. S., 1974, Binding of human liver f3-galactosidases to plant lectins insolubilized on agarose, Biochem. Biophys. Res. Commun. 56:193.
O’Brien, J. S., 1973, Ganglioside Storage Disease, in: Advances in Human Genetics (Vol. 3) (H. Harris and K. Hirschhorn, eds.), p. 39, Plenum Press, New York.
Obrien, J. S., Okada, S., Fillerup, D. L., Veath, M. L., Adornato, B., Brenner, P. H., and LeRoy, J. G., 1971, -1-al —SachsDisease: Prenatal Diagnosis. Science 172:61.
O’Brien, J. S., Miller, A. L., Loverde, A. W., and Veath, M. L., 1973, Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts, Science, 181:753.
Opie, I., and Opie, P., 1951, The Oxford Dictionary of Nursery Rhymes, Oxford University Press, Oxford
Paillot, B., Remy, N. H., Thomas, D., and Brown, G.. 1974, Path. Biol. 22:491.
Papahadjopoulos, G. P., and Mayhew, E., 1974, Cellular uptake of cyclic AMP captured within phospho-lipid vesicles and effect on cell-growth behaviors. Biorhim. Biophys. Acta 363:404.
Patel, V. P., Koppang, N., Patel, B., and Zeman, W., 1974, p-phenylenediamine-mediated peroxidase deficiency in English setters with neuronal ceroid-lipofuscinosis, Lab. Invest. 30:366.
Phillips, N. C., Robinson, D., Winchester, B. G., and Jolly, R. D., 1974, Mannosidosis in Angus cattle: the enzymic defect, Biochem. J. 137:363.
Polmar, S. H., Wetzler, E. M., Stern, R. C., and Hirschhorn, R., 1975, Restoration of in vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency, Lancet 2:743.
Philippart, M., Franklin, S. S., and Gordon, A., 1972, Reversal of an inborn sphingolipidosis (Fabrv’s disease) by kidney transplantation, Ann. Intern. Med. 77:195.
Poznansky, M. J., and Chang, T. M. S., 1974, Comparison of the enzyme kinetics and immunological properties of catalase immobilized by microencapsulation and catalase in free solution for enzyme replacement, Biochem. Biophys. Acta 334:103.
Rifkind, R. A., 1966, Destruction of injured red cells in vivo, Amer. J. Med. 41:711.
Roberts, D. F., Chavez, J., and Court, S. D. M., 1970, The genetic component in child mortality, Arch. Disease Childhood 45:33.
Scriver, C. R., 1967, Treatment in medical genetics, in: Proc. 3rd Int. Congr. Human Genetics (Chicago, Sept.) U. F. Crow, and J. V. Neel, eds.), p. 45, The Johns Hopkins Press, Baltimore.
Scriver, C. R., 1969, Treatment of inherited disease: realized and potential, Med. Clin. N. Amer. 53:941
Scriver, C. R., 1971, Mutants: consumers with special needs, Nutr. Rev. 29:155.
Scriver, C. R., 1974, Enzyme therapy and induction in genetic disease: pox or pax, Proc. 4th Int. Birth Defects Conf. (A. G. Motulsky, and W. Lentz, eds.), p. 114, Excerpta Medica ICS 310, Amsterdam
Striver, C. R., and Rosenberg, L. E., 1973, Amino Acid Metabolism and Its Disorders, W. B. Saunders Ltd., Philadelphia.
Scriver, C. R., Neal, J. L., Saginur, R., and Clow, A., 1973, The frequency of genetic disease and congenital malformation among patients in a pediatric hospital, Can. Med. Assoc. Journal 108:1111.
Scriver, C. R., Chesney, R. W., and McInnes, R. R., 1976, Genetic aspects of renal tubular transport: diversity and topology of carriers, Kidney Int. 9:149.
Silman, I. H., and Katchalski, E., 1966, Water-insoluble derivatives of enzymes, antigens, and antibodies, Ann. Rev. Biochem. 35:873.
Sly, W. S., Glaser, J. G., Roozen, K., Brot, E., and Stahl, P., 1974, Enzyme replacement studies with ßglucuronidase deficiency, in: Enzyme Therapy in Lysosomal Storage Diseases U. M. Tager, G. J. M. Hooghwinkel, and W. Th. Daims, eds.), p. 288, North-Holland Publishing Co., Amsterdam.
Suzuki, K., Suzuki, Y., and Fletcher, T. F., 1972, Further studies on galactocerebroside ß-galactosidase in globoid cell leukodystrophy, in: Sphingolipids,Sphingolipidoses and Allied Disorders (B. W. Volk and S. M. Aronson, eds.), p. 487, Plenum Press, New York.
Sweeley, C. C., Mapes, C. A., Krivit, W., and Desnick, R. J., 1972, Chemistry and metabolism of glycosphingolipids in Fabry’s disease, in: Sphingolipids, Sphingolipidoses and Allied Disorders (B. W. Volk and S. M. Aronson, eds.), p. 287, Plenum Press, New York.
Synder, P. D. Jr., Wold, F., Bernlohr, R. W., Dullum, C., Desnick, R. J., Krivit, W., and Condie, R. M., 1974, Enzyme therapy II: Purified human a-galactosidase A. Stabilization to heat and protease aggregation by complexing with antibody and by chemical modification, Biochem. Biophys. Acta 350:432.
Thoene, J. C., Oshima R. G., Crawhall, J. C., Olson D. L., and Schneider, J. A., 1976, Cystinosis intracellular cystine depletion by aminothiols in vitro and in vivo. J. Clin. Invest. 58:180
Trimble, B. K., and Doughty, J. H., 1974, The amount of hereditary disease in human populations, Ann. Human Genet. (Land.) 38:199.
Wold, F., 1973, Chemical modification of enzymes, in: Enzyme Therapy in Genetic Diseases, Birth Defects (Original Article Series, Vol. 9) (R. J. Desnick, R. W. Bernlohr, and W. Krivit, eds.), p. 46, The Williams & Wilkins Company, Baltimore.
World Health Organization, 1972, Genetic Disorders: Prevention, Treatment and Rehabilitation, Tech. Rept. SerNo. 497, Geneva.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1977 Plenum Press, New York
About this chapter
Cite this chapter
Scriver, C.R. (1977). A Biomedical View of Enzyme Replacement Strategies in Genetic Disease. In: Chang, T.M.S. (eds) Biomedical Applications of Immobilized Enzymes and Proteins. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-2610-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4684-2610-6_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-2612-0
Online ISBN: 978-1-4684-2610-6
eBook Packages: Springer Book Archive